In a study published online in the Journal of Clinical Oncology on May 6, 2013, researchers reported results of a study investigating menopausal hormonal therapy (MHT) use and the incidence of ovarian cancer. When a report from the Women’s Health Initiative linked breast cancer incidence to the use of menopausal hormonal therapy in 2002, there … Continued
A new study shows that rates of ovarian cancer decreased around the same time that the use of hormone replacement therapy dropped off. Overall, for women over 50, rates decreased by 21 percent from 1995 to 2008, from 38 cases out of 100,000 women to 30 out of 100,000. However, the author cautions that this … Continued
A new article summarizes treatment options for women with recurrent ovarian cancer. The article includes information about when to treat a recurrence, what agents are available and the goals of therapy. Read the full article here
According to a large new study published May 2, 2013 in the prestigious journal Nature, researchers have found that endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup, and may respond to targeted drugs already being tested in clinical trials. Furthermore, they found that genomic alterations in uterine serous tumors—the … Continued
Last fall, the Alliance convened a ground-breaking meeting in Washington, DC, to consider some of the most challenging topics facing the ovarian cancer community. A group of researchers, oncologists, regulatory experts, advocates and industry representatives attempted to answer questions such as: “How can more women be treated where they live?” “How can we facilitate increased … Continued
Researchers at the University of Wisconsin, including former OCRF grantee Stephen Rose, MD, conducted a qualitative research study looking at how patients with recurrent ovarian cancer experience humor to gain insight into the feasibility of using humor as a “therapeutic adjunct.” The study, which was published in the March 2013 issue of the International Journal … Continued
Ovarian cancer survivor Susan Leighton reports on her experience at the American Association of Cancer Researchers meeting, which took place in April 2013. For the second year in a row I had the privilege of being selected to attend the Scientist-Survivor Program (SSP) of the American Association of Cancer Researchers. The SSP program was established … Continued
Earlier this month at the annual meeting of the American Academy of Cancer Research, OCRF grantee Joyce Liu, MD, MPH presented research showing that 20% of women with platinum-resistant ovarian cancer responded to an experimental drug that targets a protein common in ovarian cancer. The small clinical trial is the first to show results from … Continued
In a small study presented at the annual meeting of the American Association of Cancer Research earlier this month, researchers from the University of Pennsylvania reported success with a new two-step immunotherapy approach to treating advanced ovarian cancer when combined with chemotherapy. The process begins with treatment with a personalized vaccine, which is created from … Continued
Women who had surgery to treat their endometriosis also lowered their risk of developing ovarian cancer. A study of approximately 600 Swedish women found that those who either had one ovary removed or had surgery to remove endometriotic tissue had a 20 to 42 percent lower risk of developing ovarian cancer. See the abstract here … Continued
In a new study of over 47,000 women with ovarian cancer, researchers found disparities in the quality of ovarian cancer care and survival according to race and socioeconomic status. Not receiving care adherent with National Comprehensive Cancer Network guidelines was a predictor of inferior survival. Women who were black, on Medicare, or uninsured were less … Continued
A study of 231 cancer patients found that the use of duloxetine (Cymbalta) reduced chemotherapy induce peripheral neuropathy. Patients either recieved Cymbalta or a placebo; in the Cymbalta arm, 59% of patients had an improvement in symptoms, whereas in the placebo arm only 38% of patients had an improvement in symptoms. The abstract is available … Continued
Get email updates about research news, action alerts, and ways to join the fight.
